This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2023 Dec 19;330(23):2304-2305.

doi: 10.1001/jama.2023.21109.

Use of Donanemab in Early Symptomatic Alzheimer Disease-Reply

Cynthia D Evans¹, John R Sims¹

Affiliations

PMID: 38112817
DOI: 10.1001/jama.2023.21109

Comment

Use of Donanemab in Early Symptomatic Alzheimer Disease-Reply

Cynthia D Evans et al. JAMA. 2023.

. 2023 Dec 19;330(23):2304-2305.

doi: 10.1001/jama.2023.21109.

Authors

Cynthia D Evans¹, John R Sims¹

Affiliation

¹ Eli Lilly and Company, Indianapolis, Indiana.

PMID: 38112817
DOI: 10.1001/jama.2023.21109

No abstract available

PubMed Disclaimer

Comment on

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Sims JR, et al. JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239. JAMA. 2023. PMID: 37459141 Free PMC article.

Similar articles

Use of Donanemab in Early Symptomatic Alzheimer Disease.
Pomara N, Imbimbo BP. Pomara N, et al. JAMA. 2023 Dec 19;330(23):2304. doi: 10.1001/jama.2023.21106. JAMA. 2023. PMID: 38112820 No abstract available.
Donanemab: First Approval.
Kang C. Kang C. Drugs. 2024 Oct;84(10):1313-1318. doi: 10.1007/s40265-024-02087-4. Epub 2024 Sep 6. Drugs. 2024. PMID: 39237715 Review.
Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial.
Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S, Collins EC, Sims JR, Mintun MA. Pontecorvo MJ, et al. JAMA Neurol. 2022 Dec 1;79(12):1250-1259. doi: 10.1001/jamaneurol.2022.3392. JAMA Neurol. 2022. PMID: 36251300 Free PMC article. Clinical Trial.
Alzheimer's drug donanemab helps most when taken at earliest disease stage, study finds.
Reardon S. Reardon S. Nature. 2023 Jul;619(7971):682-683. doi: 10.1038/d41586-023-02321-1. Nature. 2023. PMID: 37460689 No abstract available.
Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide.
Cehlar O, Skrabana R, Revajova V, Novak M. Cehlar O, et al. Bratisl Lek Listy. 2018;119(4):201-204. doi: 10.4149/BLL_2018_037. Bratisl Lek Listy. 2018. PMID: 29663816 Review.

See all similar articles

Cited by

Amyloid-beta antibody treatment in Alzheimer's disease : An update on recent data and outlook on implementation in clinical routine.
Stögmann E, Schmidt R. Stögmann E, et al. Wien Klin Wochenschr. 2025 Mar;137(5-6):182-188. doi: 10.1007/s00508-024-02466-7. Epub 2024 Nov 6. Wien Klin Wochenschr. 2025. PMID: 39505779 Free PMC article. Review.
Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease.
Solopova E, Romero-Fernandez W, Harmsen H, Ventura-Antunes L, Wang E, Shostak A, Maldonado J, Donahue MJ, Schultz D, Coyne TM, Charidimou A, Schrag M. Solopova E, et al. Nat Commun. 2023 Dec 12;14(1):8220. doi: 10.1038/s41467-023-43933-5. Nat Commun. 2023. PMID: 38086820 Free PMC article.
Favorable long-term cognitive outcomes following recurrent ARIA linked to amyloid-lowering therapies: two cases.
Zavarella M, Cecchetti G, Rugarli G, Ghirelli A, Bottale I, Orlandi F, Spinelli EG, Santangelo R, Caso F, Calloni SF, Vezzulli PQ, Falini A, Magnani G, Agosta F, Filippi M. Zavarella M, et al. J Neurol. 2025 Jan 24;272(2):168. doi: 10.1007/s00415-025-12910-x. J Neurol. 2025. PMID: 39853424
Standardized statistical framework for comparison of biomarkers: Techniques from ADNI.
Harvey DJ, Tosun D, Jack CR Jr, Weiner M, Beckett LA; Alzheimer's Disease Neuroimaging Initiative. Harvey DJ, et al. Alzheimers Dement. 2024 Oct;20(10):6834-6843. doi: 10.1002/alz.14160. Epub 2024 Aug 13. Alzheimers Dement. 2024. PMID: 39138886 Free PMC article.
A Framework for Best Practices and Readiness in the Advent of Anti-Amyloid Therapy for Early Alzheimer's Disease in Asia.
Lee JH, Jia J, Ji Y, Kandiah N, Kim S, Mok V, Pai MC, Senanarong V, Suh CH, Chen C. Lee JH, et al. J Alzheimers Dis. 2024;101(1):1-12. doi: 10.3233/JAD-240684. J Alzheimers Dis. 2024. PMID: 39058448 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information